文献速递核素与放射性配体治疗放射性药物与辐射防护

使用全自动一次性卡套系统生产161Tb-DOTATOC:将161Tb引入临床的第一步

161Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of 161Tb into the Clinic.
PubMed 文献 · J Nucl Med · 2023-05-18

本研究旨在表征161Tb并开发符合药品生产质量管理规范的全自动合成与质量控制方案,以生产161Tb-DOTATOC供临床使用。结果显示161Tb的放射核纯度与放射化学纯度均超过99.9%,内毒素低于允许范围(175 IU/mL),产物在24小时内放射化学纯度≥95%,活性水平为1.0-7.4 GBq/20 mL。

要点

  • 161Tb的放射核纯度与放射化学纯度均超过99.9%,内毒素低于175 IU/mL。
  • 全自动卡套模块可生产临床适用规格的161Tb-DOTATOC,活性为1.0-7.4 GBq/20 mL。
  • 产物放射化学纯度在24小时内保持≥95%。

核心结论

  • 161Tb具备适合临床使用的特征,所开发的合成方案可保证注射用161Tb-DOTATOC的高产率与安全制备。
  • 该研究途径可转化至其他DOTA衍生肽,因此161Tb可成功应用于临床放射性核素治疗。

研究设计与样本

  • 研究对通过高通量反应堆中子辐照160Gd并放射化学分离靶材料生产的161Tb进行表征,检测放射核纯度、化学纯度、内毒素水平和放射化学纯度。
  • 将161Tb引入全自动卡套模块合成161Tb-DOTATOC,并用高效液相色谱、气相色谱和内毒素试验评估产物的身份、放射化学纯度、乙醇和内毒素含量。

主要发现

  • 在所描述条件下生产的161Tb与无载体添加的177Lu类似,pH为1-2,放射核纯度和放射化学纯度均超过99.9%,内毒素水平低于允许范围(175 IU/mL)。
  • 开发了高效稳健的161Tb-DOTATOC全自动生产与质量控制程序,临床适用规格和活性水平为20 mL中1.0-7.4 GBq。
  • 采用色谱方法进行的质量控制确认产品在24小时内稳定,放射化学纯度≥95%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

161Tb is an interesting radionuclide for application in the treatment of neuroendocrine neoplasms' small metastases and single cancer cells because of its conversion and Auger-electron emission. Tb has coordination chemistry similar to that of Lu; therefore, like 177Lu, it can stably radiolabel DOTATOC, one of the leading peptides used for the treatment of neuroendocrine neoplasms. However, 161Tb is a recently developed radionuclide that has not yet been specified for clinical use. Therefore, the aim of the current work was to characterize and specify 161Tb and to develop a protocol for the synthesis and quality control of 161Tb-DOTATOC with a fully automated process conforming to good-manufacturing-practice guidelines, in view of its clinical use. Methods: 161Tb, produced by neutron irradiation of 160Gd in high-flux reactors followed by radiochemical separation from its target material, was characterized regarding its radionuclidic purity, chemical purity, endotoxin level, and radiochemical purity (RCP) in analogy to what is described in the European Pharmacopoeia for no-carrier-added 177Lu. In addition, 161Tb was introduced into a fully automated cassette-module synthesis to produce 161Tb-DOTATOC, as used for 177Lu-DOTATOC. The quality and stability of the produced radiopharmaceutical in terms of identity, RCP, and ethanol and endotoxin content were assessed by means of high-performance liquid chromatography, gas chromatography, and an endotoxin test, respectively. Results: 161Tb produced under the described conditions showed, as the no-carrier-added 177Lu, a pH of 1-2, radionuclidic purity and RCP of more than 99.9%, and an endotoxin level below the permitted range (175 IU/mL), indicating its appropriate quality for clinical use. In addition, an efficient and robust procedure for the automated production and quality control of 161Tb-DOTATOC with clinically applicable specifications and activity levels, that is, 1.0-7.4 GBq in 20 mL, was developed. The radiopharmaceutical's quality control was also developed using chromatographic methods, which confirmed the product's stability (RCP ≥ 95%) over 24 h. Conclusion: The current study demonstrated that 161Tb has appropriate features for clinical use. The developed synthesis protocol guarantees high yields and safe preparation of injectable 161Tb-DOTATOC. The investigated approach could be translated to other DOTA-derivatized peptides; thus, 161Tb could be successfully applied in clinical practice for radionuclide therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Favaretto C, Grundler PV, Talip Z, et al. 161Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of 161Tb into the Clinic. J Nucl Med. 2023. PMID: 37201956. doi:10.2967/jnumed.122.265268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。